◆Research findings by a group led by Professor Hiroaki Kitaoka of the Medical School of Medical School and Cardiovascular Medicine at Medical School have been published in *The New England Journal of Medicine*, an international academic journal published by the Massachusetts Medical Society.
Release Date:
Evaluation of the Efficacy of Mamakumten for Non-obstructive Hypertrophic Cardiomyopathy
Research findings by a group led by Professor Hiroaki Kitaoka of Medical School of Medical School and Cardiovascular Medicine Medical School have been published in *The New England Journal of Medicine*, an international academic journal published by the Massachusetts Medical Society.
Hypertrophic cardiomyopathy is a form of cardiomyopathy characterized by cardiac hypertrophy primarily caused by sarcomere gene mutations. It is broadly classified into obstructive hypertrophic cardiomyopathy, which involves obstruction, and non-obstructive hypertrophic cardiomyopathy, which does not involve obstruction; both can lead to sudden death and heart failure.Mabacumten is approved as a treatment for symptomatic obstructive hypertrophic cardiomyopathy in patients with heart failure symptoms. However, its efficacy for non-obstructive hypertrophic cardiomyopathy has not been established.
Kochi University participated in the international Phase 3 clinical trial (the Odyssey-HCM trial) for this drug as the lead site in Japan, collaborating with leading institutions worldwide to evaluate its efficacy in treating non-obstructive hypertrophic cardiomyopathy.
Although no statistically significant difference was observed, an improvement in patients’ subjective symptoms was noted. Additionally, improvements were observed in biomarkers used to assess cardiac workload. These findings demonstrate the efficacy of this drug in patients with hypertrophic cardiomyopathy.